Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
World game at war: why some European nations have threatened a World Cup boycott 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
